Pomerantz LLP

Please review this complaint. Click to Contact Us about joining this ACTION >>

Questions? Ask Us

Heron Therapeutics, Inc.

We are investigating Heron Therapeutics, Inc. (HRTX) (“Heron” or the “Company”) for potential violations of the federal securities laws. 

On May 1, 2019, Heron announced receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) on April 30, 2019 regarding Heron’s New Drug Application (“NDA”) for HTX-011 for the management of postoperative pain.  Heron advised investors that “[t]he CRL stated that the FDA is unable to approve the NDA in its present form based on the need for additional [Chemistry, Manufacturing, and Controls] and non-clinical information.”  On this news, Heron’s stock price fell $3.93 per share, or 18.13%, to close at $17.75 per share on May 1, 2019.